Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Redburn Atlantic

Redburn Atlantic upgraded shares of Charles River Laboratories International (NYSE:CRL - Free Report) from a neutral rating to a buy rating in a report issued on Friday, Marketbeat.com reports. The firm currently has $182.00 target price on the medical research company's stock, down from their previous target price of $188.00.

A number of other research analysts have also issued reports on CRL. Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Barclays boosted their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. reduced their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $171.85.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded down $1.66 during mid-day trading on Friday, reaching $136.99. 196,799 shares of the company were exchanged, compared to its average volume of 990,067. The firm's 50-day simple moving average is $130.77 and its two-hundred day simple moving average is $162.06. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $254.15. The firm has a market cap of $6.73 billion, a PE ratio of 913.50, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.27 earnings per share. Equities analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CRL. Cornerstone Investment Partners LLC raised its holdings in shares of Charles River Laboratories International by 3.7% in the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock worth $358,000 after purchasing an additional 69 shares during the period. Metis Global Partners LLC lifted its holdings in shares of Charles River Laboratories International by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after acquiring an additional 72 shares in the last quarter. Two Sigma Securities LLC boosted its position in Charles River Laboratories International by 4.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock worth $366,000 after purchasing an additional 81 shares during the period. Wahed Invest LLC increased its holdings in Charles River Laboratories International by 6.5% in the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after purchasing an additional 81 shares in the last quarter. Finally, Brooklyn Investment Group raised its position in Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after purchasing an additional 86 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).